Haemonetics (HAE) Director Johnson Lloyd Emerson Receives 2,538 RSUs

What Happened

• Johnson Lloyd Emerson, a director of Haemonetics Corporation (HAE), received an award of 2,538 restricted stock units (RSUs) on 2026-07-24. The Form 4 reports an "A" (award/grant) transaction; no purchase price or immediate cash value is listed because these are contingent equity awards rather than open-market trades.

Key Details

• Transaction date: 2026-07-24; Form 4 filed 2026-07-28 (timely).
• Award: 2,538 RSUs (transaction code A). No per-share price or dollar value reported on the Form 4.
• Vesting: RSUs vest 100% on the first anniversary of the grant (i.e., 2027-07-24) (Footnote F1).
• Conversion: Each RSU represents the contingent right to one share of common stock upon vesting (Footnote F2).
• Shares owned after transaction: not specified in the filing.
• Filing appears timely (filed within the standard Section 16 reporting window).

Context

• RSU grants are typically compensation awards to align management/director interests with shareholders; they do not represent immediate stock purchases or sales. The RSUs only become actual shares if and when they vest per the stated schedule.